D.B. Root & Company LLC Has $352,000 Stock Holdings in Thermo Fisher Scientific Inc. $TMO

D.B. Root & Company LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 22.4% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 869 shares of the medical research company’s stock after selling 251 shares during the period. D.B. Root & Company LLC’s holdings in Thermo Fisher Scientific were worth $352,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. CBIZ Investment Advisory Services LLC raised its stake in Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 33 shares during the last quarter. Anderson Financial Strategies LLC bought a new position in shares of Thermo Fisher Scientific during the first quarter valued at $30,000. Keystone Global Partners LLC bought a new stake in Thermo Fisher Scientific during the first quarter worth about $31,000. DiNuzzo Private Wealth Inc. increased its holdings in Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 61 shares in the last quarter. Finally, HighMark Wealth Management LLC raised its holdings in shares of Thermo Fisher Scientific by 140.6% in the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock valued at $31,000 after buying an additional 45 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. William Blair began coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an “outperform” rating on the stock. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday. Scotiabank upgraded Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price on the stock in a report on Friday, July 11th. Raymond James Financial reiterated an “outperform” rating and issued a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Robert W. Baird boosted their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. Fifteen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $585.37.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 30,066 shares of company stock valued at $14,182,963 in the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $543.88 on Monday. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $610.97. The firm’s 50 day moving average is $482.58 and its 200-day moving average is $446.77. The company has a market capitalization of $205.38 billion, a PE ratio of 31.46, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same period in the previous year, the business earned $5.37 EPS. The company’s revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.